Zai Lab Ltd News Today

Zai Lab Ltd. (ZLAB) and Innoviva Specialty Therapeutics announced Monday that China's National Medical Products Administration or NMPA has approved Zai Lab's New Drug Application for XACDURO (sulbactam-durlobactam) to treat hospital-acquired and ventilator-associated pneumonia caused by Acinetobacter baumannii-calcoaceticus complex in China.

Osaka, Japan and Waltham, Massachusetts, April 30, 2024 - ONO Pharmaceutical, Co., Ltd., and Deciphera Pharmaceuticals, Inc. today announced that on April 29, 2024 , ONO and Deciphera entered...

Zai Lab Ltd.'s (ZLAB) partner Novocure Ltd. (NVCR) announced on Wednesday that its phase 3 clinical trial in Tumor Treating Fields therapy for patients with 1-10 brain metastases from non-small cell lung cancer or NSCLC, has met its primary endpoint by demonstrating significant improvement in intracranial progression.

Operator: Hello, ladies and gentlemen. Thank you for standing by, and welcome to Zai Lab Full Year 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Strategic Progress and Financial Highlights Reflect Company's Growth Trajectory

On January 3, 2024, Ying Du, Chairperson & CEO of Zai Lab Ltd (NASDAQ:ZLAB), executed a sale of 8,380 shares in the company, according to a recent SEC Filing.

Here are Thursday's biggest calls on Wall Street.

-- Zai Lab said late Tuesday that Chinas National Healthcare Security Administration has added Vyvgart, Nuzyra, and Zejula to its 2023 reimbursement drug list. Vyvgart was included in the list for...

Operator: Hello, ladies and gentlemen. Thank you for standing by, and welcome to Zai Labs Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in listen-only mode.

Mirati Therapeutics (NASDAQ:MRTX – Get Free Report) and BriaCell Therapeutics (OTCMKTS:BCTXF – Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, valuation and risk. Volatility & Risk Mirati Therapeutics has a beta […]